Porcine Offal Turns Export Compliance into a Formulation Task

The UK update on Aujeszky’s disease in the United States does not change the core message for processors: porcine offal cannot be treated in documentation as a minor ingredient. After a case was confirmed on 30 April 2026 at a commercial Iowa farm, the United Kingdom first suspended imports of fresh domestic porcine offal from the United States. For meat products containing such offal, it requires treatment C or higher.

The instruction clearly distinguishes muscle meat from offal. For pork products without domestic porcine offal, treatment A or higher remains sufficient. If a product contains both components and they are mixed before treatment, the entire product must undergo at least treatment C. If the offal is treated before it is mixed with skeletal muscle meat, the strengthened requirement applies only to that component.

This is not a customs detail. It requires raw-material specifications that separate species, tissue type, origin and treatment stage. A formulation, a production order and export documentation must describe the same physical flow. Otherwise, compliance cannot be demonstrated reliably, even when the finished product appears homogeneous.

The 18 September update also confirms that animal-health events can change the commercial value of a particular animal fraction. For buyers, sausage manufacturers and foreign-trade operators, the lesson is to integrate offal, heat treatment and certificates from product design onward. Export eligibility is built before mixing, not while shipping documents are being prepared.